Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia

Haematologica. 2008 Jan;93(1):e16-7. doi: 10.3324/haematol.11933.

Abstract

LBH589 is a novel cinnamic hydroxamic acid analog (HAA) pan-histone deacetylase inhibitor (HDACi) currently in early phase clinical development.

Publication types

  • Case Reports

MeSH terms

  • Disease Progression
  • Electrolytes / metabolism
  • Enzyme Inhibitors / pharmacology*
  • Fatal Outcome
  • Histone Deacetylase Inhibitors*
  • Humans
  • Hydroxamic Acids / chemistry
  • Hydroxamic Acids / pharmacology*
  • Indoles
  • Leukemia, Myeloid, Acute / complications*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Middle Aged
  • Panobinostat
  • Tumor Lysis Syndrome / complications
  • Tumor Lysis Syndrome / etiology*

Substances

  • Electrolytes
  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Indoles
  • Panobinostat